Jump to content

Encore: Why Xgeva (denosumab) is used more than Zometa (zoledronic acid)


Recommended Posts

Our special guest speaker today, endocrinologist Dr Jane Holmes-Walker), told us that Xgeva (denosumab) is being more used today than Zometa (zoledronic acid) to prevent skeletal events (broken bones, or compressed spine bones) in metastatic prostate cancer.


We published a key study on this back in September 2012.


If you wish to see that study again, click on this sentence.



Link to comment
Share on other sites


This topic is now archived and is closed to further replies.

  • Create New...